202 related articles for article (PubMed ID: 38600391)
21. Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming.
Wang Y; Tong C; Dai H; Wu Z; Han X; Guo Y; Chen D; Wei J; Ti D; Liu Z; Mei Q; Li X; Dong L; Nie J; Zhang Y; Han W
Nat Commun; 2021 Jan; 12(1):409. PubMed ID: 33462245
[TBL] [Abstract][Full Text] [Related]
22. The NOTCH-FOXM1 Axis Plays a Key Role in Mitochondrial Biogenesis in the Induction of Human Stem Cell Memory-like CAR-T Cells.
Kondo T; Ando M; Nagai N; Tomisato W; Srirat T; Liu B; Mise-Omata S; Ikeda M; Chikuma S; Nishimasu H; Nureki O; Ohmura M; Hayakawa N; Hishiki T; Uchibori R; Ozawa K; Yoshimura A
Cancer Res; 2020 Feb; 80(3):471-483. PubMed ID: 31767627
[TBL] [Abstract][Full Text] [Related]
23. Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling.
Weber EW; Parker KR; Sotillo E; Lynn RC; Anbunathan H; Lattin J; Good Z; Belk JA; Daniel B; Klysz D; Malipatlolla M; Xu P; Bashti M; Heitzeneder S; Labanieh L; Vandris P; Majzner RG; Qi Y; Sandor K; Chen LC; Prabhu S; Gentles AJ; Wandless TJ; Satpathy AT; Chang HY; Mackall CL
Science; 2021 Apr; 372(6537):. PubMed ID: 33795428
[TBL] [Abstract][Full Text] [Related]
24. TET2 guards against unchecked BATF3-induced CAR T cell expansion.
Jain N; Zhao Z; Feucht J; Koche R; Iyer A; Dobrin A; Mansilla-Soto J; Yang J; Zhan Y; Lopez M; Gunset G; Sadelain M
Nature; 2023 Mar; 615(7951):315-322. PubMed ID: 36755094
[TBL] [Abstract][Full Text] [Related]
25. Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies.
Tantalo DG; Oliver AJ; von Scheidt B; Harrison AJ; Mueller SN; Kershaw MH; Slaney CY
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34035114
[TBL] [Abstract][Full Text] [Related]
26. Single-cell ATAC-seq maps the comprehensive and dynamic chromatin accessibility landscape of CAR-T cell dysfunction.
Jiang P; Zhang Z; Hu Y; Liang Z; Han Y; Li X; Zeng X; Zhang H; Zhu M; Dong J; Huang H; Qian P
Leukemia; 2022 Nov; 36(11):2656-2668. PubMed ID: 35962059
[TBL] [Abstract][Full Text] [Related]
27. Chimeric antigen receptor T cell persistence and memory cell formation.
McLellan AD; Ali Hosseini Rad SM
Immunol Cell Biol; 2019 Aug; 97(7):664-674. PubMed ID: 31009109
[TBL] [Abstract][Full Text] [Related]
28. Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma.
Wang X; Walter M; Urak R; Weng L; Huynh C; Lim L; Wong CW; Chang WC; Thomas SH; Sanchez JF; Yang L; Brown CE; Pichiorri F; Htut M; Krishnan AY; Forman SJ
Clin Cancer Res; 2018 Jan; 24(1):106-119. PubMed ID: 29061640
[No Abstract] [Full Text] [Related]
29. GSNOR overexpression enhances CAR-T cell stemness and anti-tumor function by enforcing mitochondrial fitness.
Niu Q; Zhang H; Wang F; Xu X; Luo Y; He B; Shi M; Jiang E; Feng X
Mol Ther; 2024 Jun; 32(6):1875-1894. PubMed ID: 38549378
[TBL] [Abstract][Full Text] [Related]
30. Deletion of Cbl-b inhibits CD8
Kumar J; Kumar R; Kumar Singh A; Tsakem EL; Kathania M; Riese MJ; Theiss AL; Davila ML; Venuprasad K
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462140
[TBL] [Abstract][Full Text] [Related]
31. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
[TBL] [Abstract][Full Text] [Related]
32. Immunophenotypic Analysis of CAR-T Cells.
de Azevedo JTC; Mizukami A; Moço PD; Malmegrim KCR
Methods Mol Biol; 2020; 2086():195-201. PubMed ID: 31707677
[TBL] [Abstract][Full Text] [Related]
33. Metabolic reprogramming via an engineered PGC-1α improves human chimeric antigen receptor T-cell therapy against solid tumors.
Lontos K; Wang Y; Joshi SK; Frisch AT; Watson MJ; Kumar A; Menk AV; Wang Y; Cumberland R; Lohmueller J; Carrizosa E; Boyerinas B; Delgoffe GM
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36914208
[TBL] [Abstract][Full Text] [Related]
34. Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma.
Sun L; Gao F; Gao Z; Ao L; Li N; Ma S; Jia M; Li N; Lu P; Sun B; Ho M; Jia S; Ding T; Gao W
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33833049
[TBL] [Abstract][Full Text] [Related]
35. Enhanced CAR-T activity against established tumors by polarizing human T cells to secrete interleukin-9.
Liu L; Bi E; Ma X; Xiong W; Qian J; Ye L; Su P; Wang Q; Xiao L; Yang M; Lu Y; Yi Q
Nat Commun; 2020 Nov; 11(1):5902. PubMed ID: 33214555
[TBL] [Abstract][Full Text] [Related]
36. Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib.
Qin JS; Johnstone TG; Baturevych A; Hause RJ; Ragan SP; Clouser CR; Jones JC; Ponce R; Krejsa CM; Salmon RA; Ports MO
J Immunother; 2020 May; 43(4):107-120. PubMed ID: 31899702
[TBL] [Abstract][Full Text] [Related]
37. CD28 Costimulatory Domain-Targeted Mutations Enhance Chimeric Antigen Receptor T-cell Function.
Boucher JC; Li G; Kotani H; Cabral ML; Morrissey D; Lee SB; Spitler K; Beatty NJ; Cervantes EV; Shrestha B; Yu B; Kazi A; Wang X; Sebti SM; Davila ML
Cancer Immunol Res; 2021 Jan; 9(1):62-74. PubMed ID: 33188139
[TBL] [Abstract][Full Text] [Related]
38. NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness.
Bachiller M; Perez-Amill L; Battram AM; Carné SC; Najjar A; Verhoeyen E; Juan M; Urbano-Ispizua A; Martin-Antonio B
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34433634
[TBL] [Abstract][Full Text] [Related]
39. CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy.
Giuffrida L; Sek K; Henderson MA; Lai J; Chen AXY; Meyran D; Todd KL; Petley EV; Mardiana S; Mølck C; Stewart GD; Solomon BJ; Parish IA; Neeson PJ; Harrison SJ; Kats LM; House IG; Darcy PK; Beavis PA
Nat Commun; 2021 May; 12(1):3236. PubMed ID: 34050151
[TBL] [Abstract][Full Text] [Related]
40. Engineering chimeric antigen receptor-T cells for cancer treatment.
Ye B; Stary CM; Li X; Gao Q; Kang C; Xiong X
Mol Cancer; 2018 Feb; 17(1):32. PubMed ID: 29448937
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
